Clinical trial NCT05984420: Comparison of LimpiAD Cream 2.5% Plus Versus Its Vehicle and and a Basic Emollient in Patients With Atopic Dermatitis
Official title: Comparative Clinical Trial Between LimpiAD 2.5% Plus Cream, Its Vehicle and a Basic Emollient in Atopic Dermatitis in Paediatric Age
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Atopic Dermatitis
Keywords: pediatric atopic dermatits
topical medical device
LimpiAD
eczema
Lead sponsor: Aileens Pharma SRL
Sponsor class: INDUSTRY
Collaborators: name: Advice Pharma Group srl
First posted: 2023-08-09
Enrollment: 200
Sex: ALL
Minimum age (years): 6
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical trial is to assess the efficacy and tolerability of LimpiAD, a medical device in the formulation of a 2.5% Plus cream, versus the Vehicle of LimpiAD 2,5% Plus cream, and versus a basic emollient in subjects with mild to moderate Atopic Dermatitis.

Detailed description: The objective of this clinical trial is to assess the efficacy and tolerability of LimpiAD, a medical device in the formulation of 2.5% Plus cream, versus the Vehicle of LimpiAD 2,5% Plus cream , and versus a basic emollient in subjects with mild to moderate Atopic Dermatitis.

STUDY DESIGN A controlled, 3-arms randomized, double-blind, multicentre clinical trial within subjects, stratified and balanced based on severity of the Atopic Dermatitis (AD) between LimpiAD 2.5% Plus cream, the Vehicle of LimpiAD 2.5% Plus cream and a basic standard treatment (basic therapy) of AD according to European Guidelines in pediatric subjects with mild to moderate AD.

SAMPLE SIZE Two hundred (200) subjects with Atopic Dermatitis, of whom at least 50 cases with mild severity Atopic Dermatitis (defined by EASI = Eczema Area and Severity Index = 1.0-7.0 and IGA= Investigator's Global Assessment =2) and 50 cases with moderate severity Atopic Dermatitis (defined by EASI 7.1-21.0 and IGA=3).

TREATMENT SCHEDULE AND METHODS Treatment with the investigational product or the control products will occur twice daily (morning and evening) for 8 weeks after cleansing of the treatment area. After the 8 weeks treatment period, the study subjects will undergo a follow-up visit after 12 weeks following the baseline visit (4 weeks after treatment completion).

Clinical assessments will be performed at baseline (T0), and after 2, 4, 8 and 12 weeks (T2, T4, T8 and T12) by means of a daily diary as a reminder.

Primary endpoint: statistically significant improvement of the EASI between T0 and T8 (p\<0.05) in the treatment arm (LimpiAD 2.5% Plus cream ) as compared to the Vehicle of LimpiAD 2.5% Plus cream.

Eligibility criteria: Inclusion Criteria:

* Subjects of both sexes, between 6 months and 16 years of age, Caucasian, in good health, whose parents/tutors provided a written and signed informed consent for participation in the study shall be enrolled. In particular, as regards parents/tutors:

  * Both parents/tutors, in case of joint custody, must provide a written and signed informed consent for the participation of the child in the study according to the instructions provided by the investigators;
  * They must accept to bring the child to the clinical trial facility on predefined visit days according to the instructions provided by the investigators;
  * They must be willing and be able to follow the trial requirements provided by the investigators.

The inclusion criteria provide that:

* Symptoms and signs compatible with a clinical diagnosis of Atopic Dermatitis should be present upon enrollment;
* The clinical severity of AD should correspond to an EASI ranging between 1.0 and 21.0 and an IGA equal to 2 or 3;
* Pruritus severity assessed by means of VAS scale ≥ 4 cm should be referred to the part of the body to be treated, as a requirement for inclusion in the study;
* The clinical assessment should envisage for the patient the indication of a moisturizing/emollient treatment as single therapy for AD (in accordance with European Guidelines on AD treatment).

Exclusion Criteria:

The following items are to be considered as exclusion criteria:

* The application of cortisone-based products on the skin to be treated in the 2 weeks prior to treatment;
* Ongoing use at baseline of antibiotics and systemic anti-inflammatory drugs for AD in the 2 weeks preceding treatment and during the study (paracetamol is allowed at dosages and indications recommended for use as an antipyretic and analgesic);
* Baseline treatment with anti-inflammatory drugs, antihistamines, antitussives and/or inhaled steroids in the 2 previous weeks, retinoids and/or immunosupressants in the previous 6 months.
* Use of systemic steroids in the 4 weeks prior to the study.
* Intense and prolonged sun exposure in the 30 days preceding the screening.
* Severe AD (EASI \> 21) or mild/moderate AD requiring any local and/or systemic treatment comprised in the prohibited treatments included in the exclusion criteria;
* Hypersensitivity to the study products.
* Acute or chronic skin diseases - except for atopic eczema - which may invalidate clinical assessments or overlap with AD skin picture;
* Systemic diseases which may affect the subject's safety or wellbeing or interfere with skin response.

Primary outcomes:
measure: Change in Eczema Area and Severity Index (EASI)
timeFrame: Baseline (T0), 2 weeks (T2), 4 weeks (T4) and 8 weeks (T8)
Secondary outcomes:
measure: Change in Investigator Global Assessment (IGA) scale for Atopic Dermatitis
timeFrame: Baseline (T0), 2 weeks (T2), 4 weeks (T4) and 8 weeks (T8)
measure: Eczema Area and Severity Index (EASI) Change
timeFrame: Baseline (T0), 2 weeks (T2), 4 weeks (T4) and 8 weeks (T8)
measure: Change in pruritus
timeFrame: Baseline (T0), 4 weeks (T4) and 8 weeks (T8)
measure: Change in sleep
timeFrame: Baseline (T0), 4 weeks (T4) and 8 weeks (T8)
measure: Change in extension and signs intensity of the target areas,
timeFrame: Baseline (T0),2 weeks (T2), 4 weeks (T4) and 8 weeks (T8)
measure: Children's Dermatology Life Quality Index (CDLQI) questionnaire
timeFrame: Baseline (T0),2 weeks (T2), 4 weeks (T4) and 8 weeks (T8)
Other outcomes:
Locations:
city: Castellammare di Stabia
country: Italy
facility: Dr. Chianese Pierluigi
state: Napoli
city: Nola
country: Italy
facility: Dr. Carlomagno Francesco
state: Napoli
city: Pomigliano d'Arco
country: Italy
facility: Dr. D'Onofrio Antonietta
state: Napoli
city: Battipaglia
country: Italy
facility: Dr. Giuseppe Ruggiero
state: Salerno
city: Salerno
country: Italy
facility: Dr. Occhinegro Aurelio
Study officials:
affiliation: ASL Salerno
name: Ruggiero Giuseppe, MD
role: PRINCIPAL_INVESTIGATOR
References: